Celgene
| Type | Subsidiary |
|---|---|
| Industry | Biotechnology |
| Founded | 1986 (1986) |
| Founder | Sol J. Barer |
| Headquarters | Summit, New Jersey, U.S. |
| Key people | Robert J. Hugin (Executive Chairman) Mark Alles (CEO) |
| Products | Revlimid Abraxane Pomalyst/Imnovid Thalomid Idhifa |
| Revenue |  $15.281 billion (2018) |
| Net income | $4.046 billion (2018) |
| Total assets | $35.480 billion (2018) |
| Total equity |  $6.161 billion (2018) |
| Number of employees | 8,852 (2018) |
| Parent | Bristol Myers Squibb |
| Website | www.bms.com |
Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS).
For detailed contact information visit location pages below.
Celgene's locations around the world
Clinical Trials sponsored by Celgene
-
CelgeneCelgene CorporationCompletatoLinfoma | CancroStati Uniti, Regno Unito
-
Celgene CorporationCompletato
-
Celgene CorporationCompletatoSindrome mielodisplastica a rischio basso o intermedio 1 (MDS)Stati Uniti
-
Celgene CorporationTerminatoCancro colorettaleAustralia, Belgio, Germania, Italia, Spagna, Svezia
-
Celgene CorporationCompletatoStudio di efficacia e sicurezza della monoterapia CC-5013 in soggetti con sindromi mielodisplasticheSindromi mielodisplasticheStati Uniti, Danimarca, Australia, Belgio, Repubblica Ceca, Francia, Germania, Grecia, Italia, Olanda, Federazione Russa, Spagna, Svezia, Svizzera, Regno Unito
-
Celgene CorporationCompletatoMieloma multiploIrlanda, Spagna, Australia, Austria, Regno Unito
-
Celgene CorporationCompletatoCancro polmonare a piccole celluleStati Uniti
-
Celgene CorporationRitiratoCancro al seno metastaticoStati Uniti
-
Celgene CorporationCompletato
-
Celgene CorporationCompletatoSindromi mielodisplasticheStati Uniti